NetworkNewsBreaks – Viking Therapeutics, Inc. (NASDAQ: VKTX) Closes $63.3M Offering
Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. (NASDAQ: VKTX), focused on developing novel therapies for metabolic and endocrine disorders, has announced the closing of an underwritten public offering of 12,650,000 shares of its common stock priced at $5 per share. The offering includes the sale of an additional 1,650,000 shares of common stock pursuant to the full exercises of the over-allotment option granted to the underwriters. A press release regarding the offering states: “The shares were sold at a price of $5.00 per share, resulting in the gross proceeds to Viking Therapeutics of approximately $63.3 Million. Viking Therapeutics currently intends to…







